Abstract
Introduction/BackgroundRisk-reducing surgery, medical prevention, and breast cancer (BC) surveillance offer the opportunity to manage BC and ovarian cancer (OC) risk in BRCA1/BRCA2/PALB2/RAD51C/RAD51D/BRIP1 cancer-susceptibility-gene (CSG) carriers, but their cost-effectiveness remains poorly...
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
